AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24341963 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based support intervention
Number of subjects: 241
Study 24251744 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) for 360 s at 30 Hz and 4 mm peak‐to‐peak displacement
Number of subjects: 30
Study 24251744 — intervention group
Group type: COMPARATOR
Intervention: Sham position (CON)
Number of subjects: 30
Study 24251744 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Number of subjects: 30
Study 20846257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 600 µg misoprostol
Number of subjects: 64
Study 20846257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 600 µg misoprostol
Number of subjects: 64
Study 18201934 — intervention group
Group type: EXPERIMENTAL
Intervention: KADIAN (morphine sulfate extended-release) with 240 mL 40% alcohol
Number of subjects: 32
Study 18201934 — intervention group
Group type: COMPARATOR
Intervention: KADIAN (morphine sulfate extended-release) with water (fasted)
Number of subjects: 32
Study 18201934 — intervention group
Group type: EXPERIMENTAL
Intervention: KADIAN (morphine sulfate extended-release) with alcohol under fasted or fed conditions
Number of subjects: 32
Study 16620710 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC)
Number of subjects: 110
Study 16620710 — intervention group
Group type: COMPARATOR
Intervention: Control group (radical surgery and general venous chemotherapy)
Number of subjects: 110
Study 12791624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aglycone form of isoflavones (daidzein and genistein)
Number of subjects: 15
Study 12791624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucoside form of isoflavones (daidzein and genistein)
Number of subjects: 15
Study 10967371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) + Folic Acid (500 microg)
Number of subjects: 127
Study 10967371 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily) + Placebo
Number of subjects: 127
Study 8641579 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ROPM program
Number of subjects: 0
Study 8641579 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3 + vincristine
Number of subjects: 0
Study 8641579 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3
Number of subjects: 0
Study 8641579 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive chemotherapy during remission induction
Number of subjects: 0
Study 8641579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0
Study 31549217 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6 (mFOLFOX6)
Number of subjects: 864
Study 29385446 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 2016
Study 29385446 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 2016
Study 29385446 — intervention group
Group type: EXPERIMENTAL
Intervention: Canada (general population)
Number of subjects: 2016
Study 29385446 — intervention group
Group type: EXPERIMENTAL
Intervention: USA (general population)
Number of subjects: 2016
Study 27068574 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity program (9-month duration, integrated into math lessons)
Number of subjects: 505
Study 24520671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral bipolar plasmakinetic enucleation and resection of the prostate (PKERP)
Number of subjects: 180
Study 24520671 — intervention group
Group type: COMPARATOR
Intervention: Transurethral bipolar plasmakinetic resection of the prostate (PKRP)
Number of subjects: 180
Study 22992267 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 900 mg capsules thrice daily (total daily dose 2.7 g per day)
Number of subjects: 0
Study 22992267 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules thrice daily
Number of subjects: 0
Study 18358737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² administered every 21 days
Number of subjects: 764
Study 16192735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐estradiol
Number of subjects: 29
Study 16192735 — intervention group
Group type: COMPARATOR
Intervention: Oral estrogens
Number of subjects: 29
Study 14673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot meal (188 g carrot purée providing 30 mg beta-carotene)
Number of subjects: 16
Study 14673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato meal (61 g tomato purée providing 30 mg lycopene)
Number of subjects: 16
Study 14673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach meal (260 g cooked chopped spinach providing 30 mg lutein)
Number of subjects: 16
Study 14673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot meal
Number of subjects: 16
Study 10601560 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP-B/VIMB
Number of subjects: 129
Study 10601560 — intervention group
Group type: COMPARATOR
Intervention: ProMACE-CytaBOM
Number of subjects: 129
Study 9342767 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum extract
Number of subjects: 0
Study 9342767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with hypericum
Number of subjects: 0
Study 8474513 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening for colorectal cancer
Number of subjects: 46551
Study 8474513 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial screening for colorectal cancer
Number of subjects: 46551
Study 8474513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 46551
Study 3513670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 40 to 400 micrograms
Number of subjects: 14
Study 3513670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 100 to 400 micrograms
Number of subjects: 14
Study 3513670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 20 to 400 micrograms
Number of subjects: 14
Study 3513670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OB) 100 and 400 micrograms
Number of subjects: 14
Study 3513670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3513670 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (ISO) 150 micrograms
Number of subjects: 14
Study 31781946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' estimates of expected survival time (EST)
Number of subjects: 179
Study 31781946 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimates of their most-likely survival scenario
Number of subjects: 179
Study 30297565 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etched
Number of subjects: 48
Study 30297565 — intervention group
Group type: COMPARATOR
Intervention: ER: YAG laser etched
Number of subjects: 48
Study 30297565 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid plus ER: YAG laser etched
Number of subjects: 48
Study 26946332 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tDCSUHCDS of M1‐DLPFC
Number of subjects: 12
Study 26946332 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tDCSUHCDS of M1‐V1
Number of subjects: 12
Study 26946332 — intervention group
Group type: COMPARATOR
Intervention: Sham c‐tDCSUHCDS
Number of subjects: 12
Study 26946332 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tDCS of M1 and V1
Number of subjects: 12
Study 24932989 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalens AO
Number of subjects: 78
Study 24932989 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTOR +3.0
Number of subjects: 78
Study 24932989 — intervention group
Group type: COMPARATOR
Intervention: Tecnis Multifocal
Number of subjects: 78
Study 23767178 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with breast cancer (study group)
Number of subjects: 240
Study 23767178 — intervention group
Group type: COMPARATOR
Intervention: Women with secure attachment (regardless of breast cancer status)
Number of subjects: 240
Study 20118124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand elevation postoperatively
Number of subjects: 113
Study 20118124 — intervention group
Group type: COMPARATOR
Intervention: No hand elevation (Control)
Number of subjects: 113
Study 18359127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.03% or 0.1%)
Number of subjects: 197
Study 18359127 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 197
Study 17285971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine Test
Number of subjects: 0
Study 14600693 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine rinse
Number of subjects: 24
Study 14600693 — intervention group
Group type: COMPARATOR
Intervention: 1% NaOCl as irrigant (Control)
Number of subjects: 24
Study 11127348 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention on universal precautions education
Number of subjects: 55
Study 8678347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis using a 13,500 ppm fluoridated pumice
Number of subjects: 36
Study 8678347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with pumice followed by application of a 2500 ppm fluoridated paste
Number of subjects: 36
Study 8678347 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis with pumice only (Control)
Number of subjects: 36
Study 1469927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg twice daily for 10 days)
Number of subjects: 203
Study 1469927 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily for 10 days)
Number of subjects: 203
Study 6362693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 24
Study 6362693 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 24
Study 6362693 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 24
Study 31303349 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6417
Study 31303349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6417
Study 29457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient artificial tears (aAT)
Number of subjects: 18
Study 29457271 — intervention group
Group type: COMPARATOR
Intervention: Refrigerated artificial tears (rAT)
Number of subjects: 18
Study 29457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning instillation of artificial tears
Number of subjects: 18
Study 29457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening instillation of artificial tears
Number of subjects: 18
Study 26954560 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 40
Study 26954560 — intervention group
Group type: COMPARATOR
Intervention: Open flap surgery (traditional surgery)
Number of subjects: 40
Study 23647918 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 30
Study 23517838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam during the procedure
Number of subjects: 2013
Study 23517838 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control subjects)
Number of subjects: 2013
Study 20682932 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist intervention
Number of subjects: 726
Study 20682932 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer intervention
Number of subjects: 726
Study 20682932 — intervention group
Group type: COMPARATOR
Intervention: Control (brochure)
Number of subjects: 726
Study 19034108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine, 0.25% (TEA group)
Number of subjects: 24
Study 19034108 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline (control group)
Number of subjects: 24
Study 16636722 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% isotretinoin
Number of subjects: 40
Study 16636722 — intervention group
Group type: COMPARATOR
Intervention: 0.05% isotretinoin
Number of subjects: 40
Study 12716237 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site collaborative care intervention (N = 57), including education, 2 visits, follow-up phone calls, and paroxetine
Number of subjects: 115
Study 12716237 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care physician (N = 58)
Number of subjects: 115
Study 12716237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 115
Study 10728741 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 1839
Study 10728741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 1839
Study 10728741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 1839
Study 10728741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1839
Study 9124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg biweekly
Number of subjects: 0
Study 9124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg biweekly with Rifampin
Number of subjects: 0
Study 9124833 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg biweekly without Rifampin
Number of subjects: 0
Study 9124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone with high bilirubin levels (> 1.2 mg/dl)
Number of subjects: 0
Study 9124833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone with normal bilirubin levels (0.7 mg/dl)
Number of subjects: 0
Study 1559334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Number of subjects: 10
Study 1559334 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Number of subjects: 10
Study 1559334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and vaginal)
Number of subjects: 10
Study 3989400 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory findings on the cervical spine by three different chiropractors
Number of subjects: 40
Study 30345939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education curriculum (implemented twice per week for 6 weeks)
Number of subjects: 131
Study 30345939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131
Study 29325289 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/d for 208 weeks
Number of subjects: 188
Study 29325289 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine 0.6 g/d for 208 weeks
Number of subjects: 188
Study 26053024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Number of subjects: 667
Study 26053024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 23490224 — intervention group
Group type: EXPERIMENTAL
Intervention: BEA2180 (50, 100 or 200 μg)
Number of subjects: 2080
Study 23490224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg)
Number of subjects: 2080
Study 23490224 — intervention group
Group type: EXPERIMENTAL
Intervention: BEA2180 (200 μg)
Number of subjects: 2080
Study 23490224 — intervention group
Group type: EXPERIMENTAL
Intervention: BEA2180 (50 and 200 μg)
Number of subjects: 2080
Study 23490224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2080
Study 21803584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic foot condition with the most push-off
Number of subjects: 7
Study 21803584 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic foot condition with the least push-off
Number of subjects: 7
Study 21803584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trailing prosthetic limb push-off impulse
Number of subjects: 7
Study 21803584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic push-off work
Number of subjects: 7
Study 19543908 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric ergometer training (EET)
Number of subjects: 62
Study 19543908 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training (RET)
Number of subjects: 62
Study 19543908 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 62
Study 16423664 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 5
Study 16423664 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon imaging
Number of subjects: 5
Study 16423664 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate (SR) imaging
Number of subjects: 5
Study 16423664 — intervention group
Group type: COMPARATOR
Intervention: Conventional echocardiographic examination
Number of subjects: 5
Study 15238405 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus cisplatin (study group)
Number of subjects: 44
Study 15238405 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (control group)
Number of subjects: 44
Study 11254234 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy at the Dead Sea
Number of subjects: 48
Study 11254234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balneotherapy)
Number of subjects: 48
Study 9146850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1.5 mg kg‐1)
Number of subjects: 10
Study 7964943 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 350 mg/m2/d plus oral leucovorin 150 mg/d
Number of subjects: 45
Study 7964943 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2/d plus oral leucovorin 150 mg/d
Number of subjects: 45
Study 3596338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at 2300 h
Number of subjects: 0
Study 3596338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg at 2300 h
Number of subjects: 0
Study 3596338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg at 2300 h
Number of subjects: 0
Study 3596338 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg bd (0800 h and 2300 h)
Number of subjects: 0
Study 3596338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at 1800 h
Number of subjects: 0
Study 3596338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg at 1800 h
Number of subjects: 0
Study 3596338 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at 1800 h
Number of subjects: 0
Study 29212965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day pitavastatin plus 10 mg/day ezetimibe
Number of subjects: 128
Study 29212965 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/day pitavastatin
Number of subjects: 128
Study 27755389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nephron blockade
Number of subjects: 166
Study 27755389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential renin-angiotensin system blockade
Number of subjects: 166
Study 27755389 — intervention group
Group type: COMPARATOR
Intervention: Baseline (Resistant Hypertension)
Number of subjects: 166
Study 25076372 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL) implantation
Number of subjects: 31
Study 25076372 — intervention group
Group type: COMPARATOR
Intervention: Limbal relaxing incisions (LRI)
Number of subjects: 31
Study 23638126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 250
Study 20652797 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-designed structures
Number of subjects: 60
Study 20652797 — intervention group
Group type: COMPARATOR
Intervention: Waxed-up and digitized structures
Number of subjects: 60
Study 18229990 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Attention (JA) intervention
Number of subjects: 58
Study 18229990 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic Play (SP) intervention
Number of subjects: 58
Study 18229990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 16368192 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-evoked allodynia
Number of subjects: 9
Study 16368192 — intervention group
Group type: COMPARATOR
Intervention: Normal brushing
Number of subjects: 9
Study 14600517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multiple micronutrient supplementation
Number of subjects: 481
Study 14600517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 10825334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (Group O4)
Number of subjects: 82
Study 10825334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV (Group O8)
Number of subjects: 82
Study 10825334 — intervention group
Group type: COMPARATOR
Intervention: Saline IV (Group C)
Number of subjects: 82
Study 8673938 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (T group)
Number of subjects: 110
Study 8673938 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 110
Study 1308714 — intervention group
Group type: COMPARATOR
Intervention: Booked mothers
Number of subjects: 391
Study 1308714 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbooked mothers
Number of subjects: 391
Study 6353843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment
Number of subjects: 112
Study 6353843 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 112
Study 31892352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h(‐ 1) for a total of 1 h
Number of subjects: 150
Study 31892352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion at increasing rates
Number of subjects: 150
Study 31892352 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 IU h(‐ 1) infusion)
Number of subjects: 150
Study 29737533 — intervention group
Group type: EXPERIMENTAL
Intervention: sutimlimab
Number of subjects: 64
Study 29737533 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 26822403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser enucleation of the prostate (DiLEP)
Number of subjects: 80
Study 26822403 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 80